Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Blood (2024) 144 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2024-205736

Published: 2024

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Sita D. Bhella, Katrina Hueniken, Osamah Jamal S. Jarallah, Melissa Teixeira Maltez, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7581.

https://doi.org/10.1182/blood-2024-211007

Published: 2024

Journal Articles

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Blood (2024) 144 (Supplement 1): 567.

https://doi.org/10.1182/blood-2024-207439

Published: 2024

Journal Articles

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Blood (2024) 144 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2024-209364

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inna Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood (2024) 144 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2024-206056

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Rintu Sharma, John Kuruvilla, Michael Crump, David Hodgson, Yangqing Deng, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Rodger E Tiedemann, Sita Bhella, Chloe Yang, Anca Prica

Blood (2024) 144 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2024-212184

Published: 2024

Journal Articles

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita D. Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2024-201539

Published: 2024

Journal Articles

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

David Hodgson, Mahmood Aminilari, Donna Liao, Xiang Y Ye, Ur Metser, Michael Crump, John Kuruvilla, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Richard Tsang, Sita D. Bhella, Danielle Rodin, Anca Prica

Blood (2023) 142 (Supplement 1): 988.

https://doi.org/10.1182/blood-2023-190983

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Matthew J. Maurer, Susan K Parsons, Jenica Upshaw, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza A Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Kerry J. Savage, Pier Luigi Zinzani, Andrew M Evens

Blood (2023) 142 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2023-175079

Published: 2023

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Blood (2022) 140 (Supplement 1): 3532–3533.

https://doi.org/10.1182/blood-2022-156571

Published: 2022

Journal Articles

Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis

Akash Parekh, Frank G. Keller, Kathleen M. McCarten, Sandy Kessel, Steve Cho, Qinglin Pei, Yue Wu, Sharon M. Castellino, Louis S. Constine, Cindy L. Schwartz, David Hodgson, Kara M. Kelly, Bradford S. Hoppe

Blood (2022) 140 (10): 1086–1093.

https://doi.org/10.1182/blood.2022016098

Published: 2022

Includes: Supplemental data

Journal Articles

The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

Andrea C. Lo, Amy Liu, Qi Liu, Yutaka Yasui, Sharon M. Castellino, Kara M. Kelly, Alex F. Herrera, Jonathan W. Friedberg, Debra L. Friedman, Cindy L. Schwartz, Samuel Bergeron-Gravel, Hitesh Dama, Kenneth B. Roberts, Louis S. Constine, David Hodgson

Blood (2021) 138 (Supplement 1): 881.

https://doi.org/10.1182/blood-2021-147678

Published: 2021

Journal Articles

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Ho-Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noemie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla, Robert Kridel

Blood (2021) 138 (Supplement 1): 1383.

https://doi.org/10.1182/blood-2021-148942

Published: 2021

NARROW

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis

The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only